Related Experiment Videos
AVP receptor antagonists in patients with CHF
1Thomas Jefferson University Hospital, Jefferson Medical College, Philadelphia, PA, USA. drms1976@gmail.com
Heart Failure Reviews
|September 4, 2008
Summary
Hyponatremia, or low serum sodium, affects 5% of acute decompensated heart failure patients. Targeting arginine vasopressin (AVP) receptor activity is a key therapeutic strategy for managing this condition.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Hyponatremia (serum sodium <130 mEq/l) is observed in 5% of patients with acute decompensated heart failure (ADHF).
- Enhanced release of arginine vasopressin (AVP) contributes to hyponatremia via V2 receptor binding, causing free-water retention.
- AVP plays a central role in hyponatremia associated with congestive heart failure (CHF).
Purpose of the Study:
- To explore therapeutic strategies targeting AVP activity in ADHF patients with hyponatremia.
- To investigate the potential of blocking AVP receptors as a treatment for hyponatremia in heart failure.
Main Methods:
- Analysis of data from the Acute Decompensated Heart Failure Registry (Adhere).
- Review of the physiological mechanisms linking AVP to hyponatremia in heart failure.
- Evaluation of receptor blockade as a therapeutic approach.
Main Results:
- Hyponatremia identified in 5% of ADHF patients at presentation.
- AVP's role in free-water retention and hyponatremia confirmed.
- Receptor blockade emerges as a focus for managing AVP-induced hyponatremia.
Conclusions:
- Hyponatremia is a significant comorbidity in ADHF.
- Blocking the V2 receptor offers a potential therapeutic avenue to counteract AVP's effects.
- Further research into AVP receptor antagonists is warranted for heart failure management.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...